Combining adaptive ultra-low-dose radiation therapy with rituximab shows promise in treating indolent B-cell non-Hodgkin ...

A man from Swindon will be taking part in a 38-mile cycle after successfully undergoing treatment for follicular lymphoma.

A man from Swindon will be taking part in a 38-mile cycle after successfully undergoing treatment for follicular lymphoma.

Follicular lymphoma survivor Troy Anderson credited acupuncture and nutrition guidance with easing treatment side effects and ...

A local Omaha woman was the first to ever receive CAR T-cell therapy as an outpatient. Doctors said it was a success, and she ...

The collaboration will fund early-stage clinical development of SB-4826, CIT’s first-in-class SUMO E1 inhibitor, for patients ...

Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.

Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

The FDA has accepted for priority review the sBLA for lisocabtagene maraleucel to treat relapsed/refractory MZL.

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in ...

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today reported financial results for the second ...

The promising results, along with a separate FDA decision, could signal a major expansion of the use of the two companies' ...